LANTHEUS HOLDINGS INC

Ber Gerard’s May 14 sale of Lantheus shares shows no market shift—insider confidence stays high, and the firm’s strong diagnostics pipeline suggests a good entry point near $100 before a potential rebound toward its 52‑week high.

Insider buying spurs confidence in Lantheus as FDA‑driven gains loom – discover how executives’ new shares reflect strong pipeline prospects and market‑worthy valuation.

Inside Lantheus Holdings’ March 2 insider trades reveal execs’ confidence, disciplined selling, and a strategic shift toward oncology diagnostics—key for investors to know.